- Home
- RMAX vs CGEN Comparison
RMAX vs CGEN Comparison
Compare RMAX & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMAX | CGEN |
|---|---|---|
| Founded | 1973 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.4M | 191.1M |
| IPO Year | 2013 | 2001 |
Fundamental Metrics
Financial Performance| Metric | RMAX | CGEN |
|---|---|---|
| Price | $9.88 | $2.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $11.40 | $5.00 |
| AVG Volume (30 Days) | 270.7K | ★ 431.3K |
| Earning Date | 05-07-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $195,929,000.00 | N/A |
| Revenue This Year | $2.62 | N/A |
| Revenue Next Year | $1.24 | $75.09 |
| P/E Ratio | $16.32 | ★ N/A |
| Revenue Growth | ★ 11.13 | N/A |
| 52 Week Low | $5.46 | $1.30 |
| 52 Week High | $11.62 | $3.24 |
Technical Indicators
Market Signals| Indicator | RMAX | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 60.78 | 35.35 |
| Support Level | $8.77 | $1.98 |
| Resistance Level | $10.32 | $2.35 |
| Average True Range (ATR) | 0.35 | 0.10 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 79.57 | 16.13 |
Price Performance
Historical ComparisonAbout RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.